184 related articles for article (PubMed ID: 36625609)
61. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
[TBL] [Abstract][Full Text] [Related]
62. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
63. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
64. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
[TBL] [Abstract][Full Text] [Related]
65. [Interest of a systematic assessment of the treatment of the lower urinary tract symptoms in the management of benign prostatic hypertrophy in general practice (1380 patients) - Study EVALURO].
Descazeaud A; Coloby P; De La Taille A; Kouri G; Mallet R; Rossi D; Rozet F; Zerbib M; Carrois F
Prog Urol; 2019 Feb; 29(2):116-126. PubMed ID: 30665818
[TBL] [Abstract][Full Text] [Related]
66. The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation.
Nickel JC; Elhilali M; Emberton M; Vallancien G;
BJU Int; 2006 Jun; 97(6):1242-6. PubMed ID: 16686719
[TBL] [Abstract][Full Text] [Related]
67. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
68. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
69. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
70. A Prospective Study to Evaluate Sexual Dysfunction and Enlargement of Seminal Vesicles in Sexually Active Men Treated for Benign Prostatic Hyperplasia by Alpha-blockers.
Sokhal AK; Sankhwar S; Goel A; Singh K; Kumar M; Purkait B; Saini DK
Urology; 2018 Aug; 118():92-97. PubMed ID: 28860050
[TBL] [Abstract][Full Text] [Related]
71. The efficacy of alfuzosin treatment in patients with prostatism.
Başar MM; Atan A; Ozergin O; Yildiz M
Int Urol Nephrol; 2001; 33(3):493-7. PubMed ID: 12230279
[TBL] [Abstract][Full Text] [Related]
72. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
Cho MC; Yoo S; Park J; Cho SY; Son H; Oh SJ; Paick JS
BJU Int; 2019 May; 123(5A):E34-E42. PubMed ID: 30582661
[TBL] [Abstract][Full Text] [Related]
73. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.
Roehrborn CG; Rosen RC
Clin Interv Aging; 2008; 3(3):511-24. PubMed ID: 18982921
[TBL] [Abstract][Full Text] [Related]
74. [Practical use of Adenoprosin in combination therapy in men with lower urinary tract symptoms].
Kasyan G R; Khodyreva L A; Grigoryan B L; Dyakov V V
Urologiia; 2024 Mar; (1):61-70. PubMed ID: 38650408
[TBL] [Abstract][Full Text] [Related]
75. Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study.
Salem R; Hairston J; Hohlastos E; Riaz A; Kallini J; Gabr A; Ali R; Jenkins K; Karp J; Desai K; Thornburg B; Casalino D; Miller F; Hofer M; Hamoui N; Mouli S
Urology; 2018 Oct; 120():205-210. PubMed ID: 30036614
[TBL] [Abstract][Full Text] [Related]
76. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
Lukacs B; Grange JC; Comet D
Urology; 2000 Apr; 55(4):540-6. PubMed ID: 10736498
[TBL] [Abstract][Full Text] [Related]
77. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH.
Gilling PJ; Barber N; Bidair M; Anderson P; Sutton M; Aho T; Kramolowsky E; Thomas A; Kaufman RP; Badlani G; Plante M; Desai M; Doumanian L; Te AE; Roehrborn CG
Can J Urol; 2022 Feb; 29(1):10960-10968. PubMed ID: 35150215
[TBL] [Abstract][Full Text] [Related]
78. [EFFECT OF TADALAFIL THAT WAS ADDITIONALLY ADMINISTERED TO PATIENTS RECEIVING AN ALPHA1-BLOCKER IN JAPANESE MEN WITH LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA].
Hayashi K; Fukagai T; Koshikiya A; Igarashi A; Morita M; Sasaki H; Ishikawa K
Nihon Hinyokika Gakkai Zasshi; 2016; 107(1):28-33. PubMed ID: 28132988
[TBL] [Abstract][Full Text] [Related]
79. The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).
Descazeaud A; Coloby P; Taille A; Karsenty G; Kouri G; Rossi D; Carrois F; Zerbib M
Presse Med; 2018; 47(7-8 Pt 1):e91-e98. PubMed ID: 30075950
[TBL] [Abstract][Full Text] [Related]
80. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
